Institute of Immunology and Immunotherapy Immunology is at the forefront of medical research and we are among the leaders of this exciting, fast-evolving field.
News £17.9m for Advanced Therapy Treatment Centre network to bolster UK clinical trial infrastructure The network includes the Midlands-Wales Advanced Therapy Treatment Centre, jointly delivered by University of Birmingham and University Hospitals Birmingham.
News BactiVac Network awarded £700k by the UK Vaccine Network Project to focus on potential epidemics
04 August 2022 New Insights into Increases in Unexplained Paediatric Hepatitis Cases Professor Deirdre Kelly and Dr Zania Stamataki, Institute of Immunology and Immunotherapy, provide insights into increases of unexplained paediatric hepatitis.
03 August 2022 Successful Round of Multiple Academic Promotions for Institute 2022 Eight academics within the Institute of Immunology and Immunotherapy at the University of Birmingham have been promoted in the 2022 academic promotion round.
04 May 2022 Institute of Immunology and Immunotherapy welcomes new Professor of Regenerative Medicine Professor Ivan Wall has been appointed as Professor of Regenerative Medicine with the Institute of Immunology and Immunotherapy at the University of Birmingham.
03 May 2022 Insights shared from patient workshop on the use of artificial intelligence at capsule endoscopy Patients suffering with inflammatory bowel disease were invited to take part in a focused workshop at the University of Birmingham to assess their experiences.
07 March 2022 Opinion: Understanding the link between oral and gut health The relationship between oral health and overall health has been a focus for research for some time, explain Professors Iain Chapple and Tariq Iqbal.
16 February 2022 New study explores unique approach to treat a rare liver disease A UK research study looking into a new approach to treat primary sclerosing cholangitis, a rare disease where the body's immune attacks its own liver.
01 February 2022 Study shows impaired antibody response to COVID-19 vaccination in blood cancer and arthritis patients being treated with widely used drug Certain blood cancer and arthritis patients have a significantly reduced antibody response to double COVID-19 vaccination in the first six months of being treated with a widely used drug, reveals a new study.